局限性前列腺癌局灶激光消融术后两年结局
34名男性参与局灶激光消融(FLA)前瞻性结局研究,其中32人在6个月和2年时接受前列腺特异性抗原(PSA)检测和磁共振成像(MRI),所有人在1年时评估泌尿和性功能。FLA对泌尿或性功能无不良影响。MRI+者中、低危复发率分别为75%和25%,MRI-者分别为22.4%和50%。结论认为MRI仅能可靠识别中危前列腺癌的野内复发,MRI+需活检,MRI-是否活检取决于低危疾病检出是否影响管理。
要点
- FLA对泌尿或性功能无不良影响。
- MRI+者野内中危复发75%、低危25%;MRI-者中危22.4%、低危50%。
- MRI仅能可靠识别中危前列腺癌的野内复发,MRI+需行消融区活检。
核心结论
- MRI能可靠识别FLA术后2年仅中危前列腺癌的野内复发。
- MRI+发现必须行消融区活检。
- MRI-男性是否行消融区活检应取决于低危疾病检出是否影响管理。
研究设计与样本
- 前瞻性结局研究,34名男性接受FLA,其中32人在6个月和2年时接受PSA检测和MRI,所有人在1年时评估泌尿和性功能。
- 干预为FLA和MRI靶向活检消融区。
- 使用双侧Wilcoxon符号秩检验比较基线与12个月时AUA症状评分和SHIM,显著性水平p=0.05。
主要发现
- FLA对泌尿或性功能无不良影响。
- MRI+者野内中危复发75%、低危复发25%。
- MRI-者野内中危复发22.4%、低危复发50%。
- PSA自基线的变化不能区分2年时MRI-且有或无癌症的病例。
临床怎么用
- 作者认为MRI+发现必须行消融区活检。
- 作者认为MRI-男性是否行消融区活检应取决于低危疾病检出是否影响管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus regarding how to assess oncological control following focal ablation of prostate cancer. OBJECTIVE: To assess quality of life and in-field recurrence following focal laser ablation (FLA). DESIGN, SETTING, AND PARTICIPANTS: Of 34 men participating in a prospective outcomes study following FLA, 32 underwent prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) at 6 mo and 2 yr. All underwent assessment of urinary and sexual function at 1 yr. INTERVENTION: FLA and MRI-targeted biopsy of the ablation zone. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The American Urological Association Symptom Score and the Sexual Health Inventory for Men at baseline and 12 mo were compared using a two-sided Wilcoxon signed-rank test with a significance level of p=0.05. The percentage of positive and negative in-field biopsies was calculated for suspicious and nonsuspicious post-ablation MRI scans. RESULTS AND LIMITATIONS: FLA was associated with no adverse impact on urinary or sexual function. For men with suspicious MRI (MRI+) findings, in-field disease recurrence of intermediate and low risk disease was detected in 75% and 25% of cases, respectively. For men with nonsuspicious MRI (MRI-) findings, in-field disease recurrence of intermediate- and low-risk disease was detected in 22.4% and 50% of cases, respectively. The change in PSA from baseline did not discriminate cases with MRI- findings with and without cancer at 2 yr. CONCLUSIONS: MRI reliably identifies in-field recurrence of only intermediate-risk prostate cancer at 2 yr after FLA. A biopsy of the ablation zone must be performed for MRI+ findings. The decision to perform an ablation-zone biopsy for men with MRI- scans should be influenced by whether detection of low-risk disease would influence management. PATIENT SUMMARY: Our study provides compelling evidence that men should undergo interval magnetic resonance imaging to assess the probability of intermediate-risk disease in the ablation zone following focal laser ablation of localized prostate cancer.
引用
- Chao B, Llukani E, Lepor H, et al. Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31100236. doi:10.1016/j.euo.2018.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。